Advertisement
Advertisement
CHRS
Coherus Oncology, Inc. Common Stock
1.27
USDSponsored
+0.01
+0.40%
Aug 07, 15:59 UTC -4
Closed
After-Market
1.32
+0.05
+3.94%
CHRS Earnings Reports
Positive Surprise Ratio
CHRS beat 18 of 43 last estimates.
42%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$17.23M
/-$0.20
Implied change from Q2 26 (Revenue/ EPS)
+20.40%
/+5.26%
Implied change from Q3 25 (Revenue/ EPS)
+48.90%
/-39.39%
Coherus Oncology, Inc. Common Stock earnings per share and revenue
On Aug 05, 2026, CHRS reported earnings of -0.19 USD per share (EPS) for Q2 26, beating the estimate of -0.20 USD, resulting in a 6.86% surprise. Revenue reached 14.31 million, compared to an expected 14.69 million, with a -2.57% difference. The market reacted with a -12.76% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.20 USD, with revenue projected to reach 17.23 million USD, implying an increase of 5.26% EPS, and increase of 20.40% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
REGENXBIO Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.05
Actual
$0.43
Surprise
+626.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
SAB Biotherapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+5.15%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
Genmab A/S ADS
Report Date
Aug 06, 2026 For Q2 26
Estimate
$3.59
Actual
$0.54
Surprise
-84.98%
Praxis Precision Medicines, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$3.73
Actual
-$2.87
Surprise
+23.14%
Halozyme Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.87
Actual
$2.27
Surprise
+21.75%
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
FAQ
What were Coherus Oncology, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Coherus Oncology, Inc. Common Stock reported EPS of -$0.19, beating estimates by 6.86%, and revenue of $14.31M, -2.57% below expectations.
How did the market react to Coherus Oncology, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -12.76%, changed from $1.45 before the earnings release to $1.26 the day after.
When is Coherus Oncology, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Coherus Oncology, Inc. Common Stock's next earnings report?
Based on 6
analysts, Coherus Oncology, Inc. Common Stock is expected to report EPS of -$0.20 and revenue of $17.23M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement